Publications by authors named "Hany Z Aly"

Background: Prematurity and congenital heart disease (CHD) are the leading causes of neonatal mortality and morbidity. Limited data are available about the outcomes of premature infants with severe CHD.

Methods: We queried The National Inpatient Database using ICD-10 codes for premature patients (<37 weeks) with severe CHD from 2016 to 2020.

View Article and Find Full Text PDF

Background: Controversial data exist about the impact of Down syndrome on outcomes after surgical repair of atrioventricular septal defect.

Aims: (A) assess trends and outcomes of atrioventricular septal defect with and without Down syndrome and (B) determine risk factors associated with adverse outcomes after atrioventricular septal defect repair.

Methods: We queried The National Inpatient Sample using International Classification of Disease codes for patients with atrioventricular septal defect < 1 year of age from 2000 to 2018.

View Article and Find Full Text PDF
Article Synopsis
  • The study examines the effects of postnatal steroid treatment on the severity of retinopathy of prematurity (ROP) and its impact on how quickly the retina develops in premature infants born at ≤32 weeks gestation or weighing ≤1500 g.
  • Out of 1695 infants analyzed, 67% received steroid therapy, revealing that higher doses and longer treatment durations significantly increased the incidence of severe ROP and delayed full vascularization of the retina.
  • The findings suggest that the use of postnatal steroids needs to be carefully considered, as they are linked to worse ROP outcomes and slower retinal development in vulnerable infants.
View Article and Find Full Text PDF

Background And Objectives: The use of inhaled nitric oxide (iNO) in +late preterm and term infants with pulmonary hypertension is Food and Drug Administration (FDA) approved and has improved outcomes and survival. iNO use is not FDA approved for preterm infants and previous studies show no mortality benefit. The objectives were 1) to determine the usage of iNO among preterm neonates <35 weeks before and after the 2010 National Institutes of Health consensus statement and 2) to evaluate characteristics and outcomes among preterm neonates who received iNO.

View Article and Find Full Text PDF

Objective: Bilirubin is a potent in vitro antioxidant. Despite repeated study, its in vivo significance has yet to be defined. Bilirubin is universally elevated in very low birthweight (VLBW) infants.

View Article and Find Full Text PDF